Dexmedetomidine: an update

PURPOSE OF REVIEW: Dexmedetomidine has evolved from a sedative adjunct to a multimodal perioperative adjunct with effects extending beyond hypnosis and analgesia. Growing interest has focused on its opioid-sparing properties, modulation of the surgical stress response, hemodynamic stabilization, organ protection, and patient-centered recovery outcomes. This review summarizes the recent clinical and translational evidence relevant to perioperative and critical care use. RECENT FINDINGS: Contemporary meta-analyses confirm consistent reductions in perioperative opioid requirements and postoperative pain. Dexmedetomidine attenuates neuroendocrine and inflammatory stress responses and provides predictable sympatholytic hemodynamic control. Emerging high-quality evidence suggests renoprotective effects and reduced postoperative acute kidney injury, whereas cardiopulmonary and neuroprotective benefits remain less definitive. Improvements in early recovery profile, including reduced delirium, smoother emergence, and shorter ICU stay, have been described, particularly in high-risk populations. Regional and pediatric applications demonstrate prolonged analgesia and reduced emergence agitation, while ICU studies indicate benefits primarily in delirium prevention and sleep quality rather than mortality. SUMMARY: Current evidence supports dexmedetomidine as a multimodal adjunct that enhances perioperative stability and recovery quality rather than a standalone anesthetic or outcome-modifying therapy. Careful patient selection and dose titration are essential.